DMAC DiaMedica Therapeutics Inc.
3.58
+0.06 (+2%)
Previous Close
3.52
Open
3.49
Price To Book
32.55
Market Cap
42805609
Shares
11,956,874
Volume
23,730
Short Ratio
Av. Daily Volume
76,555
NewsSee all news
- DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
- DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
- OTC Markets Group Announces Quarterly Index Performance and Rebalancing
- The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
- DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Latest News
- DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
- DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
- OTC Markets Group Announces Quarterly Index Performance and Rebalancing
- The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
- DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
- UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
- IPO Outlook For The Week: Proteins, Fashion And Finance